BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 208 filers reported holding BRIDGEBIO PHARMA INC in Q2 2021. The put-call ratio across all filers is 1.95 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,404 | +21.6% | 584,146 | -23.5% | 0.03% | +52.9% |
| Q1 2023 | $12,663 | +61.4% | 763,746 | -25.8% | 0.02% | +54.5% |
| Q4 2022 | $7,848 | -99.9% | 1,029,946 | -24.6% | 0.01% | -42.1% |
| Q3 2022 | $13,585,000 | +262.1% | 1,366,746 | +230.7% | 0.02% | +375.0% |
| Q2 2022 | $3,752,000 | -48.6% | 413,246 | +248.6% | 0.00% | -55.6% |
| Q1 2021 | $7,302,000 | – | 118,546 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |